Osamu Hataji

2.1k citations

73 papers · 1.2k indexed · h-index 17

Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 31
- Chronic Obstructive Pulmonary Disease (COPD) Research 14
- Lung Cancer Diagnosis and Treatment 13
- Respiratory Support and Mechanisms 7
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 6
Hematology top 5%
Internal Medicine top 5%
Oncology top 10%
- Lung Cancer Research Studies 14
- Cancer Immunotherapy and Biomarkers 9
- Colorectal Cancer Treatments and Studies 7
Hepatology top 10%

Co-authors: Osamu Taguchi Esteban C. Gabazza Yukihiko Adachi Tetsu Kobayashi Hisamichi Yuda Koichiro Yamakado Kentaro Ito Atsuhiro Nakatsuka
Cited by: Pulmonary and Respiratory Medicine Hematology Internal Medicine
Journals: Journal of Clinical Oncology (2 papers)American Journal of Respiratory and Critical Care Medicine (5 papers)Scientific Reports (1 paper)
Partner nations: Japan United States Sweden

In The Last Decade

Osamu Hataji

66 papers receiving 1.2k citations

Peers

Countries citing papers authored by Osamu Hataji

Since Specialization

Citations

This map shows the geographic impact of Osamu Hataji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osamu Hataji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osamu Hataji more than expected).

Fields of papers citing papers by Osamu Hataji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osamu Hataji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osamu Hataji. The network helps show where Osamu Hataji may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Osamu Hataji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Osamu Hataji Line = papers co-authored together Osamu Hataji links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study International Journal of COPD ·Kazuhiro Yatera,Zhang Wang,Yoko Shibata,Nobuhisa Ishikawa,Tetsuya Homma,Kiyoyasu Fukushima,Osamu Hataji,Yoshikazu Inoue,Hiroki Kawabata,Keisuke Miki,Kazuhiro Sato,Kazunori Tobino,Makoto Yoshida,Takeo Ishii,Risako Ito,T Kobayashi,Shinya Kawamatsu,Chris Compton,Paul Jones	2025	0
2	A case of tracheal stenosis due to anaplastic thyroid carcinoma treated using the stent‐in‐stent method Thoracic Cancer ·Tadashi Sakaguchi,Maki Ohi,Yoichi Nishii,Osamu Hataji	2023	1
3	Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions Scientific Reports ·Yoichi Nishii,Tadashi Sakaguchi,Seiya Esumi,Maki Esumi,Yuki Nakamura,Yūta Suzuki,Kentaro Ito,Kentaro Fujiwara,Hiroki Yasui,Atsushi Ito,Tomohito Tarukawa,Tatsuki Tsuruga,Corina N. D’Alessandro‐Gabazza,Taro Yasuma,Hajime Fujimoto,Fumihiro Asano,Esteban C. Gabazza,Tetsu Kobayashi,Osamu Taguchi,Osamu Hataji	2023	3
4	Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma Anticancer Research ·Atsushi Ito,Tomohito Tarukawa,Yūta Suzuki,Tadashi Sakaguchi,Kentaro Ito,Kentaro Fujiwara,Yoichi Nishii,Osamu Taguchi,Hiroki Yasui,Motoshi Takao,Osamu Hataji	2023	1
5	Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan COPD Journal of Chronic Obstructive Pulmonary Disease ·Paul Jones,Osamu Hataji,Yoshimi Suzukamo,Bruce Crawford,Yoko Sakai,Takeo Ishii,Keiko Sato,Eri Sasaki,Kenichi Hashimoto,Toru Oga	2023	3
6	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 ESMO Open ·Kentaro Ito,Masahiro Morise,Kazushige Wakuda,Osamu Hataji,Tadasuke Shimokawaji,Kosuke Takahashi,Naoki Furuya,Yoshihiro Takeyama,Yasuhiro Gotô,Tetsuya Abe,Terufumi Kato,Sachiko Ozone,Satoshi Ikeda,Yoshihito Kogure,Toshihiko Yokoyama,M. Kimura,Hiroshige Yoshioka,Kenta Murotani,Masashi Kondo,Hideo Saka	2021	33
7	An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor Clinical Lung Cancer ·Tadashi Sakaguchi,Yasumasa Kokubo,Kazuki Furuhashi,Yuki Nakamura,Yūta Suzuki,Kentaro Ito,Kentaro Fujiwara,Yoichi Nishii,Osamu Taguchi,Osamu Hataji	2021	8
8	FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial) Journal of Thoracic Oncology ·Hidetoshi Hayashi,Kimio Yonesaka,Shunichi Sugawara,Yuki Sato,Koichi Azuma,Shinya Sakata,Motoko Tachihara,Satoshi Ikeda,Toshihide Yokoyama,Osamu Hataji,Yukihiro Yano,Katsuya Hirano,Haruko Daga,Hiroshi Okada,Kazuko Sakai,Yasutaka Chiba,Kazuto Nishio,Nobuyuki Yamamoto,Kazuhiko Nakagawa	2021	1
9	Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323 Translational Lung Cancer Research ·Toshiyuki Kozuki,Naoyuki Nogami,Osamu Hataji,Yoshio Tsunezuka,Nobuhiko Seki,Toshiyuki Harada,Nobukazu Fujimoto,Akihiro Bessho,Kei Takamura,Kazuhisa Takahashi,Miyako Satouchi,Terufumi Kato,Takehito Shukuya,Natsumi Yamashita,Hiroaki Okamoto,Tetsu Shinkai	2020	4
10	<p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p> International Journal of COPD ·Masakazu Ichinose,Yasushi Fukushima,Yoshikazu Inoue,Osamu Hataji,Gary T. Ferguson,Klaus F. Rabe,Nobuya Hayashi,Hiroshi Okada,Mami Takikawa,Eric Bourne,Shaila Ballal,Kiernan DeAngelis,Magnus Aurivillius,Paul Dorinsky,Colin Reisner	2019	12
11	<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p> International Journal of COPD ·Masakazu Ichinose,Yasushi Fukushima,Yoshikazu Inoue,Osamu Hataji,Gary T. Ferguson,Klaus F. Rabe,Nobuya Hayashi,Hiroshi Okada,Mami Takikawa,Eric Bourne,Shaila Ballal,Kiernan DeAngelis,Magnus Aurivillius,Colin Reisner,Paul Dorinsky	2019	14
12	Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria Respiratory Investigation ·Tadashi Sakaguchi,Kentaro Ito,Kazuki Furuhashi,Yuki Nakamura,Yuta Suzuki,Yoichi Nishii,Osamu Taguchi,Osamu Hataji	2019	36
13	Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer Thoracic Cancer ·Yuki Nakamura,Tetsu Kobayashi,Yoichi Nishii,Yūta Suzuki,Haruko Saiki,Kentaro Ito,Fumiaki Watanabe,Kota Nishihama,Taro Yasuma,Corina N. D’Alessandro‐Gabazza,Koji Katsuta,Hajime Fujimoto,Esteban C. Gabazza,Osamu Taguchi,Osamu Hataji	2018	7
14	Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System American Journal of Respiratory Cell and Molecular Biology ·Masahiro Naito,Osamu Taguchi,Tetsu Kobayashi,Takehiro Takagi,Corina N. D’Alessandro‐Gabazza,Yuki Matsushima,Daniel Boveda-Ruiz,Paloma Gil-Bernabe,Takahiro Μatsumoto,Ayshwarya-Lakshmi Chelakkot-Govindalayathil,Masaaki Toda,Atsushi Yasukawa,Osamu Hataji,John Morser,Yoshiyuki Takei,Esteban C. Gabazza	2013	23
15	Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon Japanese Journal of Radiology ·Hiroaki Arakawa,Takeshi Johkoh,Fumikazu Sakai,Masahiko Kusumoto,Osamu Hataji,Osamu Taguchi	2011	12
16	Increased circulating levels of thrombin‐activatable fibrinolysis inhibitor in lung cancer patients American Journal of Hematology ·Osamu Hataji,Osamu Taguchi,Esteban C. Gabazza,Hisamichi Yuda,Corina N. D’Alessandro‐Gabazza,Hajime Fujimoto,Yoichi Nishii,Tatsuya Hayashi,Koji Suzuki,Yukihiko Adachi	2004	38
17	Thrombin-activatable Fibrinolysis Inhibitor and Protein C Inhibitor in Interstitial Lung Disease American Journal of Respiratory and Critical Care Medicine ·Hajime Fujimoto,Esteban C. Gabazza,Osamu Hataji,Hisamichi Yuda,Corina Nayade D'Alessandro-Gabazza,Mariko Nakano,Omar E. Franco,Tatsuya Hayashi,Koji Suzuki,Yukihiko Adachi,Osamu Taguchi	2003	36
18	Intratracheal Administration of Activated Protein C Inhibits Bleomycin-induced Lung Fibrosis in the Mouse American Journal of Respiratory and Critical Care Medicine ·Hiroki Yasui,Esteban C. Gabazza,Shigenori Tamaki,Tetsu Kobayashi,Osamu Hataji,Hisamichi Yuda,Shino Shimizu,Koji Suzuki,Yukihiko Adachi,Osamu Taguchi	2001	116
19	Long-term Inhalation of High-dose Nitric Oxide Increases Intraalveolar Activation of Coagulation System in Mice American Journal of Respiratory and Critical Care Medicine ·Tetsu Kobayashi,Esteban C. Gabazza,Shino Shimizu,Hiroki Yasui,Hisamichi Yuda,Osamu Hataji,Kazuo Maruyama,Toru Yamauchi,Koji Suzuki,Yukihiko Adachi,Osamu Taguchi	2001	10
20	Protein C Anticoagulant System in Patients with Interstitial Lung Disease American Journal of Respiratory and Critical Care Medicine ·Hiroyasu Kobayashi,Esteban C. Gabazza,Osamu Taguchi,Hideo Wada,Hiroyuki Takeya,Junji Nishioka,Hiroki Yasui,Tetsu Kobayashi,Osamu Hataji,Koji Suzuki,Yukihiko Adachi	1998	57

About Osamu Hataji

Osamu Hataji is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Issues, ethics and legal aspects, having authored 73 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (31 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Lung Cancer Research Studies (14 papers), Lung Cancer Diagnosis and Treatment (13 papers), Cancer Immunotherapy and Biomarkers (9 papers), Respiratory Support and Mechanisms (7 papers), Colorectal Cancer Treatments and Studies (7 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (734 citations), Hematology (205 citations) and Internal Medicine (68 citations). Osamu Hataji has collaborated with scholars based in Japan, United States and Sweden. Frequent co-authors include Osamu Taguchi, Esteban C. Gabazza, Yukihiko Adachi, Tetsu Kobayashi, Hisamichi Yuda, Koichiro Yamakado, Kentaro Ito, Atsuhiro Nakatsuka, Hajime Fujimoto and Kan Takeda. Their work appears in journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact